CNBX Pharmaceuticals Inc. Annual Report - How They Did This Year

This review covers CNBX Pharmaceuticals Inc.'s performance for the fiscal year that ended on August 31, 2025.

First off, it's helpful to know that CNBX Pharmaceuticals is classified as a "smaller reporting company" and an "emerging growth company." This means it's a relatively small company that's still in its early growth stages, which often comes with different opportunities and risks compared to larger, more established businesses.

Looking at the company's market value, as of February 28, 2025, the total value of its common stock held by public investors (not insiders) was approximately $251,840. This was based on a share price of $0.0076 per share. This indicates a very small market capitalization, often referred to as a 'micro-cap' or 'penny stock' company. As of November 20, 2025, there were 553,962,206 shares of common stock outstanding.

Key Takeaways:

• CNBX Pharmaceuticals Inc. is categorized as a "smaller reporting company" and an "emerging growth company," reflecting its early growth stage.
• As of February 28, 2025, the company's public common stock had a market value of approximately $251,840, with shares priced at $0.0076 each.
• As of November 20, 2025, the company had 553,962,206 shares of common stock outstanding.